| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Oxfenicine targets carnitine palmitoyltransferase I (CPT-I), the rate-limiting enzyme in mitochondrial fatty acid oxidation. By inhibiting CPT-I, it blocks the transport of long-chain fatty acids into the mitochondria, thereby shifting energy metabolism from fatty acids to glucose. This metabolic switch is cardioprotective during ischaemia.
|
|---|---|
| ln Vitro |
In vitro, oxfenicine acts as a CPT-I inhibitor. Its activity is assessed using enzyme assays with purified CPT-I or mitochondrial preparations, measuring the inhibition of palmitoyl-CoA oxidation. It protects heart cells from necrotic tissue damage during ischaemia. It improves whole-body glucose tolerance and insulin sensitivity in high-fat diet-induced obese mice.
|
| ln Vivo |
In vivo, oxfenicine protects the heart from necrotic tissue damage during ischaemia. It improves whole-body glucose tolerance and insulin sensitivity in high-fat diet-induced obese mice with insulin resistance. By inhibiting CPT-I and shifting metabolism towards glucose oxidation, it provides cardioprotection and metabolic benefits.
|
| Enzyme Assay |
The in vitro enzyme assay for oxfenicine measures its ability to inhibit carnitine palmitoyltransferase I (CPT-I) activity. These cell-free assays use mitochondrial preparations or purified CPT-I and measure the oxidation of palmitoyl-CoA. The compound's inhibitory potency (IC50) is determined by measuring the reduction in enzyme activity.
|
| Cell Assay |
In vitro cellular assays for oxfenicine assess its effects on fatty acid oxidation and glucose metabolism. Cells are treated with oxfenicine, and the rates of fatty acid oxidation and glucose oxidation are measured. Its cardioprotective effects can be assessed in cardiomyocyte cultures exposed to ischaemic conditions.
|
| Animal Protocol |
In vivo animal studies for oxfenicine have been conducted in mouse models of ischaemia and insulin resistance. It protects the heart from necrotic tissue damage during ischaemia and improves whole-body glucose tolerance and insulin sensitivity in high-fat diet-induced obese mice.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for oxfenicine are not extensively detailed in the available literature. As a small molecule, its pharmacokinetic properties would be important for its in vivo efficacy. It is a prodrug that is transaminated to 4-hydroxyphenylglyoxylic acid. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for oxfenicine are not extensively detailed in the available literature. As a CPT-I inhibitor, its toxicity profile is likely related to its mechanism of action. However, its cardioprotective effects and metabolic benefits suggest a manageable safety profile. It is intended for research purposes only.
|
| Additional Infomation |
L-4-hydroxyphenylglycine is the L-enantiomer of 4-hydroxyphenylglycine and also the enantiomer of D-4-hydroxyphenylglycine. Olfenidine is a non-esterified fatty acid (NEFA) myocardial metabolism inhibitor. Olfenidine has been reported in Daphnia pulex, with relevant data. Olfenidine is a carnitine palmitoyltransferase I (CPT-1) inhibitor involved in cardiac fatty acid metabolism. Animal studies have shown that oopenidine has a cardioprotective effect during ischemia. See also: N-(4-hydroxyphenyl)glycine (note moved here).
Oxfenicine (CAS 32462-30-9) is a CPT-I inhibitor and a derivative of L-phenylglycine. It protects the heart from necrotic tissue damage during ischaemia and improves glucose tolerance and insulin sensitivity. It has a molecular formula of C8H9NO3 and a molecular weight of 167.16. It is a research compound and is not approved for clinical use. |
| Molecular Formula |
C8H9NO3
|
|---|---|
| Molecular Weight |
167.16196
|
| Exact Mass |
167.058
|
| CAS # |
32462-30-9
|
| PubChem CID |
36143
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
365.8±32.0 °C at 760 mmHg
|
| Melting Point |
240ºC (dec.)
|
| Flash Point |
175.0±25.1 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.633
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
164
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=C(C=CC(=C1)O)[C@@H](C(=O)O)N
|
| InChi Key |
LJCWONGJFPCTTL-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C8H9NO3/c9-7(8(11)12)5-1-3-6(10)4-2-5/h1-4,7,10H,9H2,(H,11,12)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-amino-2-(4-hydroxyphenyl)acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~4.55 mg/mL (~27.22 mM)
DMSO : ~1 mg/mL (~5.98 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (11.96 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9823 mL | 29.9115 mL | 59.8229 mL | |
| 5 mM | 1.1965 mL | 5.9823 mL | 11.9646 mL | |
| 10 mM | 0.5982 mL | 2.9911 mL | 5.9823 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
